Its came away long way since 2013 without digging into shareholders pockets with ongoing dilution , and now cash postive ,entering biggest health system on a approved FDA and next China ...etc.
Making more cash postive then MSB , and cheaper then RAP and BIT .
Also a massive organic growth potential here.
Yet only a Mcap of $30m ,Work that out ?
